You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201781 - 201790 of 207725 results
  1. Development of topical formulations for delivery of next generation mTOR inhibito

    SBC: TRANSDERM, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): We discovered that the inducible keratins 6a and 6b, mutations in which can result in the skin and nail disorder pachyonychia congenita (PC), contain regulatory motifs in their 5'-untranslated regions that make them susceptible to mTOR inhibitors, including rapamycin. Using RNA profiling and immunohistochemistry of foot sole biopsies taken from PC lesions ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Novel mechanism-based targeted approach to rheumatoid arthritis

    SBC: SIGNABLOK, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder that causes chronic inflammation of the joints. RA affects about 1.5 million Americans and costs society more than 40 billion each year. Despite advances in therapy, RA has no cure. Current treatments of RA include non-steroidal anti- inflammatory drugs, corticosteroids, and disease modifyi ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Topically-delivered Mutation-specific Gene Targeting for Epidermolytic Ichthyosis

    SBC: Exicure, Inc.            Topic: NIAMS

    DESCRIPTION (provided by applicant): AuraSense Therapeutics (AST), along with Northwestern University, is applying a recently developed technology using oligonucleotide-functionalized nanoparticles (called spherical nucleic acids or SNAs) to control protein expression. These easily synthesized nanoparticles can have either DNA or RNA shells, and are less than 50 nm in hydrodynamic diameter. SNA co ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Targeted Enzyme Replacement Therapy for Rare Forms of Osteogenesis Imperfecta

    SBC: BIOSTRATAGIES LC            Topic: NIAMS

    DESCRIPTION (provided by applicant): The long-term goal of this project is to develop an effective protein replacement therapeutic (PRT) for patients affected with rare forms of Osteogenesis imperfecta, OI-VIII (deficiency in prolyl 3-hydroxylase 1; P3H1)and OI-VII (deficiency in cartilage associated protein CRTAP). These PRTs will integrate the safety and cost advantages of plant-based bioproduct ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Evaluation of Novel Cyclophilin D Inhibitors for Mitochondrial Disease Therapy

    SBC: SCYNEXIS, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Myopathies and other clinical disorders arising from genetic abnormalities of the mitochondrial respiratory chain collectively affect as many as 1 in 8000 individuals, representing in aggregate a significant disease burden, even though the specific underlying genetic lesions are each quite rare. Despite the need for therapeutic strategies to prevent or slow the ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Orthopedic Tissue Tension Sensor

    SBC: FOCUSSTART, LLC            Topic: NIAMS

    DESCRIPTION (provided by applicant): In orthopedic surgery, surgeons have to handle not only bone but also the surrounding soft tissue, including muscle, fascia, tendon, ligament and capsule. Successful handling of these tissues is often the key to high reproducibility, good soft tissue healing, and restoration of overall function. However, there are no widely used, robust methods for intra-opera ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Stem cell therapy for improved fixation of cementless total hip replacements

    SBC: AFFINERGY, LLC            Topic: NIAMS

    DESCRIPTION (provided by applicant): Through modern surgical advancements, total hip replacements (THR) have become one of the most successful implant procedures to date. Even though long-term success rates are high, the staggering number of THR proceduresper annum (~200,000 in the United States alone) results in thousands of failed implants each year. Most implants fail through aseptic loosening ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Multiplexed Assays for Improving Rheumatoid Arthritis Diagnostics

    SBC: PROGNOSYS BIOSCIENCES, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): There is a need for multiplexed assay technologies that enable diagnostics and detailed characterization of rheumatoid arthritis. In this project we plan to discover new rheumatoid arthritis biomarkers and implement them in a panel of multiplexed assays. We propose a novel approach that offers significant advances over existing methods, including the ability to ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Advanced Micro-patterned Wound Dressings for Enhanced Epithelialization

    SBC: Sharklet Technologies Inc.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Nearly 12 million wounds are treated in U.S. emergency departments every year. Skin wounds such as severe burns, large trauma wounds, or non-healing/chronic wounds that are too extensive or complex to close by natural healing are often reconstructed using autologous skin grafts. Although autologous skin grafts are currently the gold standard in complex wound re ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Coincident light/ultrasound therapy to treat acne vulgaris and atopic dermatitis

    SBC: SONIC TECH, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Sonic Tech Inc. is developing a unique energy-based therapy called CLENS (Coincident Light Energy and Non-focused ultraSound). Using two well-established clinical energy sources in a novel way, the technology is intended to treat dermal diseases caused by biofilms, a bacterially generated slime layer. Biofilms shield bacteria from attack by both antibiotics an ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government